NASDAQHealth CareBiotechnologySnapshot 2026-08-31
Reading REGN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Regeneron grows sales about 12% a year with new drug launches. Profit margins stay strong near 78%. The company controls costs and tax rates well. FDA fast-track programs speed product approvals.
Disappointing trial data and legal setbacks could hurt future sales. Profit margins may fall below guidance. Revenue growth could slow below 7%.
The price is about 8% below our fair value near $733. Analysts expect roughly 12% revenue growth. Our fair value is 9% below the Street median, reflecting some caution.
Breaks if: Effective tax rate rises above 14% in FY26
Breaks if: Gross margin falls below 77% in FY26
Pipeline progress stalls or FDA fast-track designations are lost
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth through innovation and strong product sales. The current thesis state is intact, supported by recent financial performance and management's commitment to advancing their clinical pipeline.
The market currently prices REGN as cheap compared to its peers, with expectations slightly below consensus. There is a low level of fragility in the stock, indicating that the current valuation is justified based on the company's performance and outlook.
Fundamentals are likely to remain strong as management continues to deliver on key priorities, such as advancing their clinical pipeline and growing product sales. However, there is a moderate risk due to the overall market environment and potential guidance cuts.
The long-term thesis hinges on the performance of the broader healthcare sector and the ability of REGN to maintain its growth trajectory. Key factors include the performance of peer companies and any changes in guidance during upcoming earnings calls.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Guidance has also improved, which adds to confidence. Additionally, the FDA approved Pasatru, enhancing the product pipeline. No new threats have emerged to weaken this view.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 7% in FY26
Overall, REGN presents a solid long-term thesis with strong management execution and a promising pipeline. Not investment advice.
